[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365840-105":59,"doc-detail-365840-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinicopathological-and-molecular-characterization-of-kras-wild-type-pancreatic-ductal-adenocarcinomas-reveals-precursor-lesions-with-oncogenic-mutations-and-fusions-in-ras-pathway-genes","Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes","","Pancreatic ductal adenocarcinomas (PDACs) with wild-type KRAS represent a small subset, yet they have been shown to carry actionable oncogenic mutations and fusions. This study evaluates clinicopathological features and outcomes in 75 patients with KRAS wild-type PDAC, with molecular profiling in 40 patients using targeted DNA/whole-exome and targeted RNA sequencing. Metastatic cases were younger than KRAS-mutated disease, while KRAS wild-type status was not prognostic. Alterations in RAS-pathway genes were frequent, actionable changes occurred in 30%, and precursors were identified in resection specimens, linking early tumorigenesis to oncogenic fusions and driver mutations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-and-molecular-characterization-of-kras-wild-type-pancreatic-ductal-adenocarcinomas-reveals-precursor-lesions-with-oncogenic-mutations-and-fusions-in-ras-pathway-genes/365840/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-and-molecular-characterization-of-kras-wild-type-pancreatic-ductal-adenocarcinomas-reveals-precursor-lesions-with-oncogenic-mutations-and-fusions-in-ras-pathway-genes/365840.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How many patients with KRAS wild-type PDAC were analyzed in the study?","Question",{"text":112,"@type":113},"The study investigated clinicopathological characteristics and outcomes of 75 patients with KRAS wild-type PDAC, and performed molecular analyses in 40 patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular alterations were frequently found in KRAS wild-type PDAC?",{"text":117,"@type":113},"Genes in the RAS pathway were frequently mutated or rearranged, including alterations in BRAF, NRAS, HRAS, EGFR, MAP2K1, FGFR1, FGFR3, and ERBB4, as well as fusions involving FGFR2, ALK, and BRAF.",{"name":119,"@type":110,"acceptedAnswer":120},"What precursor lesions were identified for KRAS wild-type PDAC?",{"text":121,"@type":113},"In 13 pancreatectomy specimens, the study identified three PanINs and two IPMNs harboring oncogenic fusions of ALK and BRAF and driver mutations in BRAF and AKT1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365840,1790198271,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Pathology  \nJ Pathol July 2025; 266: 337–351  \nPublished online 2 May 2025 in Wiley Online Library (wi[leyonlinelibrary.com](leyonlinelibrary.com) DOI: 10.1002/path.6432)[)](leyonlinelibrary.com) DOI: 10.1002/path.6432)[ DOI:](leyonlinelibrary.com) DOI: 10.1002/path.6432)[ 10.1002/path.6432](leyonlinelibrary.com) DOI: 10.1002/path.6432)  \nORIGINAL ARTICLE  \nClinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes  \nKazuhiro Toriyama 1,2†, Katsuhiro Masago 1†, Noriko Shibata 1 , Masataka Haneda 1 , Takamichi Kuwahara3, Seiji Natsume4, Shota Kobayashi 1 , Yasuko Fujita 1 , Eiichi Sasaki 1 , Kenji Yamao5, Hiroki Kawashima2, Yasuhiro Shimizu4, Kazuo Hara3, Yasushi Yatabe6 and Waki Hosoda 1 *  \n1 Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan  \n2 Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan  \n3 Department of Gastroenterology, Aichi Cancer Center, Nagoya, Japan  \n4 Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan  \n5 Department of Gastroenterology, Narita Memorial Hospital, Toyohashi, Japan  \n6 Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan  \n*Correspondence to: W Hosoda, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. [E-mail:](E-mail: whosoda@aichi-cc.jp)[ whosoda@aichi-cc.jp](E-mail: whosoda@aichi-cc.jp)  \n†These authors contributed equally to this work.  \nAbstract  \nPancreatic ductal adenocarcinomas (PDACs) with wild-type KRAS constitute a small fraction of PDACs, and these tumors were recently shown to harbor frequent actionable oncogenic mutations and fusions. However, the clinicopathological features of KRAS wild-type PDAC have not been well studied. Additionally, precancerous lesions occurring in patients with KRAS wild-type PDACs have rarely been characterized. Here, we investigated the clinicopathological characteristics and outcomes of 75 patients with KRAS wild-type PDAC. Molecular analyses were performed in 40 patients using targeted DNA and whole-exome sequencing and targeted RNA sequencing. We demonstrated that patients with metastatic PDAC with wild-type KRAS were younger (median 59.5 years) than those with mutated KRAS (median 67 years, p \u003C 0.000055). The wild-type KRAS status was not a signiﬁcant prognostic factor for metastatic disease. Molecularly, genes in the RAS pathway are frequently mutated or rearranged (46%, 16/35), including mutations in BRAF, NRAS, HRAS, EGFR, MAP2K1, FGFR1, FGFR3 and ERBB4 and fusions of FGFR2 (FGFR2::CCDC147, FGFR2::CAT, FGFR2::TXLNA), ALK (STRN::ALK, EML4::ALK), and BRAF  \n(TRIP11::BRAF). Mismatch repair deﬁciency was identiﬁed in 10%(4/39) of patients. Potentially actionable alterations were identiﬁed frequently in KRAS wild-type PDACs (30%, 12/40), in which nontubular-type carcinomas were signiﬁcantly enriched with actionable alterations compared with tubular adenocarcinomas [67%(6/9) versus 16%(5/31); p = 0.007]. Finally, we investigated the precursors of PDACs in 13 pancreatectomy specimens from patients with KRAS wild-type PDAC. We identiﬁed three pancreatic intraepithelial neoplasias (PanINs) and two intraductal papillary mucinous neoplasms (IPMNs) harboring oncogenic fusions of ALK and BRAF and driver mutations in BRAF and AKT1. This study suggests that in the context of unmutated KRAS, PDAC is driven by alternative oncogenic mutations or fusions of RAS pathway genes, which may be introduced during the early phase of tumorigenesis.  \n© 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great  \nBritain and Ireland.  \nKeywords: pancreatic ductal adenocarcinoma; wild-type KRAS; fusion; next-generation sequencing; precursor; PanIN; IPMN  \nReceived 2 September 2024; Revised ","cbCaieD1yeOkGipC","https://ap.wps.com/l/cbCaieD1yeOkGipC","pdf",10053295,15,"English","# Abstract\n# Introduction","[{\"question\":\"How many patients with KRAS wild-type PDAC were analyzed in the study?\",\"answer\":\"The study investigated clinicopathological characteristics and outcomes of 75 patients with KRAS wild-type PDAC, and performed molecular analyses in 40 patients.\"},{\"question\":\"What molecular alterations were frequently found in KRAS wild-type PDAC?\",\"answer\":\"Genes in the RAS pathway were frequently mutated or rearranged, including alterations in BRAF, NRAS, HRAS, EGFR, MAP2K1, FGFR1, FGFR3, and ERBB4, as well as fusions involving FGFR2, ALK, and BRAF.\"},{\"question\":\"What precursor lesions were identified for KRAS wild-type PDAC?\",\"answer\":\"In 13 pancreatectomy specimens, the study identified three PanINs and two IPMNs harboring oncogenic fusions of ALK and BRAF and driver mutations in BRAF and AKT1.\"}]","Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes | PDF",1790162595,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82bb976801fe4f76e512fcbf97a7023f.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87adfce713b8917a354f4101a14f77d6.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90bd49b0584e9dde71fef53efcc4d939.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edc38c2286344b216f1447beb602e8a4.webp",980,1385]